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In this issue ofCell StemCell, Marion et al. (2009) report that efficient production of iPSCs requires active telo-
merase, which allows the rejuvenation of telomeres to a state similar to that observed in embryonic stem
cells, even in iPSCs generated from old donor cells.The recent discovery that differentiated
cells can be reprogrammed to an embry-
onic stem cell (ESC)-like pluripotent state,
so-called induced pluripotent stem cells
(iPSCs), by the expression of just a few
transcription factors in somatic cells from
both mice and humans (Yamanaka, 2007)
has led to renewed hope for patient-
specific stem cell therapies. The success-
ful utilization of iPSCs in therapy will
require themaintenance of genomic stabi-
lity and cell survival to ensure long-term
function of iPSC-derived cells following
engraftment. A key player for these
requirements is the enzyme telomerase,
which functions to ensure stability of the
ends of chromosomes and to prevent cell
senescence by completing the replication
of telomeres. Indeed, unlikemost differen-
tiated somatic cells, abundant levels of
telomerase activity are a well-established
feature of ESCs (Thomson et al., 1998).
However, nuclear reprogramming of
somatic cells to a pluripotent state does
not necessarily guarantee reactivation of
functional telomerase and extension of
telomeres, as evidenced by unusually
short telomeres observed in cloned sheep
(Shiels et al., 1999). In this issue of Cell
StemCell, Marion, Blasco, and colleagues
now report the detailed effects of nuclear
reprogrammingof somatic cells into iPSCs
on telomerase and telomeres (Marion
et al., 2009). Their findings demonstrate
telomerase-dependent rejuvenation of
telomeres in iPSCs, derived from normal
cells taken from either young or old mice,
with telomeres that eventually reach
lengths similar to that observed in ESCs.
The two components of the telomerase
holoenzymatic complex that are essential
for activity are the telomerase RNA com-
ponent (Terc) and the catalytic compo-
nent, telomerase reverse transcriptase(Tert). Thus, the Terc knock-out (/)
mouse strain lacks functional telomerase
and is characterized by continuous telo-
mere shortening from one generation to
the next, eventually leading to telomere
dysfunction, premature aging, and
a reduced lifespan (Blasco et al., 1997).
However, telomerase-independent
mechanisms for telomere lengthening
have been observed during very early
embryogenesis and could conceivably
also come into play to restore telomere
length during the generation of iPSCs (Liu
et al., 2007). Using the Terc/ mouse
strain, Marion et al. (2009) now show that
the efficiency of iPSC generation is greatly
diminished in the absence of telomerase
and that Terc/ iPSCs fail to produce
any viable chimeric mice. Furthermore,
the authors show that telomere length in
Terc/ iPSCs is shorter than that
observed in the Terc/ fibroblasts from
which they were derived, unlike iPSCs
generated from wild-type fibroblasts.
Moreover, this reduced efficiency in iPSC
generation can be largely compensated
for by reintroduction of a wild-type Terc
allele back into the Terc/ genome, via
breeding to Terc+/ mice. Telomere
lengthening is once again observed in the
iPSCsgenerated fromfibroblasts obtained
from the F1 Terc+/ embryos, but not the
F1 Terc/ embryos, concomitant with
a reduction in the frequency of dysfunc-
tional telomeres. These observations
demonstrate that telomere length mainte-
nance and long-term proliferative capacity
of iPSCs is dependent on telomerase.
Previous studies by Blasco and
colleagues (Gonzalo et al., 2006) have
shown that epigenetic modification of
telomeric chromatin in mice, namely the
prevention of methylation of histone H3
and H4 at the telomeres, effects an elon-Cell Stem Celgation of telomeres in normal somatic
cells from these mice. Interestingly, Mar-
ion et al. (2009) also show in the present
study that both murine ESCs and iPSCs
have reduced levels of histone methyla-
tion at telomeres, relative to the primary
fibroblasts from which the iPSCs were
derived. Furthermore, the exchange of
DNA between telomeres has been shown
to occur at an elevated frequency in cells
in which histone methylation is abrogated
(Gonzalo et al., 2006) andalsooccurs at an
elevated frequency in both ESCs and
iPSCs (Marion et al., 2009). Together,
these observations provide initial evi-
dence that telomeric chromatin is also
successfully ‘‘re-programmed’’ in iPSCs,
to acquire an epigenetic signature similar
to that observed for ESCs. This reprog-
ramming of telomeric chromatin into
a more relaxed state may indeed be
required to allow access of telomerase to
the end of the telomere and subsequent
telomere lengthening (Figure 1), although
this has yet to be formally demonstrated.
Given the importance of telomerase to
the restoration of telomeres during iPSC
generation, it is important to understand
how this process is regulated. Like ESCs,
it has already been demonstrated that
iPSCs have elevated levels of telomerase
activity relative to the somatic cells from
which they derive (Yamanaka, 2007; Mar-
ion et al., 2009). Thus, it is quite possible
that the expression of Terc and/or Tert is
elevated during the nuclear reprogram-
ming of somatic cells to iPSCs, in partic-
ular Tert, which has been shown to be
the key component that limits telomerase
activity in various types of normal somatic
cells and adult stem cells (Bodnar et al.,
1998; Allsopp et al., 2003). One of the
best-characterized transactivators of
Tert in some types of somatic cells is thel 4, February 6, 2009 ª2009 Elsevier Inc. 95
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PreviewsFigure 1. Telomere Length Regulation during Nuclear Reprogramming of Fibroblasts to iPS
Cells
Telomeres form a loop structure at the very end of the chromosome, which protects the end and also
prevents telomerase from associating with the 30 terminal end of the telomere.Marion et al. show that telo-
meres are lengthened by telomerase during 3 or 4 factor reprogramming of fibroblasts, from young or old
wild-type mice, to iPS cells (left side), achieving a size similar to that observed in cultured ESCs derived
from the blastocyst. Telomeric chromatin is also demethylated during nuclear reprogramming (Marion
et al., 2009), which is proposed to facilitate the relaxation of telomeric chromatin, allowing telomerase
access to the telomere 30 end and subsequent synthesis of new telomeric DNA (red line). In telomerase
deficient cells, like those from Terc/ mice, telomeric chromatin is presumably demethylated as well;
however, telomerase cannot bind to the telomere or synthesize new telomeric DNA (right side). Therefore,
critically short telomeres observed in Terc/ cells are not repaired and remain critically short in Terc/
iPSCs (Marion et al., 2009). This, in turn, adversely affects cell proliferation and greatly limits the number of
iPSCs obtained.proto-oncogene c-Myc, which coinciden-
tally is one of the four genetic factors used
in the seminal studies demonstrating the
development of iPSCs (Knoepfler, 2008).
However,Marion et al. (2009) convincingly
show that 3-factor iPSCs, generatedusing
only Oct4, Nanog, and Klf4, show similar
levels of telomerase activation as
observed for 4-factor iPSCs. Thus, the
mechanism for telomerase activation dur-
ing iPSC nuclear reprogramming remains
obscure. Possible regulatory events aff-
ecting the switch in telomerase activity
that should be addressed in future studies
include transactivation of the Terc and/or
Tert genes, as well as posttranslational
modification of telomerase and modifica-
tion of telomeric chromatin.96 Cell Stem Cell 4, February 6, 2009 ª2009The discovery of iPSCs holds great
promise for creatingnewmethods tostudy
mechanisms for different diseases and the
development of customized patient-
specific therapies. One potential therapy
of high interest is the repair of damaged
or aged tissue in elderly individuals using
‘‘rejuvenated’’ iPS-derived cells created
from cells donated by the patient. If during
the nuclear reprogramming stage, the
telomeres fail to be regenerated to lengths
typically observed in young cells, then the
high proliferative stress that the iPS-
derived cells encounter, either pre- or
post-transplant, could very well cause
premature senescence of the iPS-derived
cells following engraftment. Marion et al.
(2009) provide an encouraging finding inElsevier Inc.regards to this potential cell therapy,
namely, that iPS cells could be readily
derived from skin fibroblasts obtained
form elderly animals with reduced telo-
mere length and that telomere length
was fully restored in these iPS cells,
achieving telomere lengths comparable
to iPS cells created from skin fibroblasts
taken from young animals. Furthermore,
they show that reintroduction of functional
telomerase into telomerase-deficient cells
harboring substantially shortened and
dysfunctional telomeres is sufficient to
allow efficient iPS cell development, the
generation of viable chimeric mice, and
restore telomere length. These observa-
tions suggest that iPS cell therapy may
one day be practical even for individuals
with abnormally short telomeres owing to
defects in telomerase. Although a number
of hurdlesmust still be cleared before iPS-
based cell therapy becomes practical, the
results from Marion et al. (2009) suggest
that reprogramming of telomerase and
telomeres may not be one them.
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